Introduction
3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins), and thiazolidinediones (TZD)
.
The multiple extra-and intracellular signalling pathways involved in EPC mobilization, recruitment, activation and function are only partly identified. In addition to the phosphatidylinositol-3-kinase (PI3K) pathway, which mediates the effects of statins on EPC, TZD exert their effects via a peroxisome proliferator-activated receptor ␥ (PPAR␥)-dependent mechanism [18, 19] . [20] . [18, 21, 22] . Several angiotensin-receptor blockers (ARB) also stimulate PPAR␥ activity, namely irbesartan, losartan and telmisartan [23] . Among them, the highly lipophilic telmisartan appears to have the strongest activating effect on the PPAR␥ pathway [24] .
The impact of nuclear transcription factor PPAR␥ on biological processes remains controversial. PPAR␥ has mainly been studied in adipocytes, but is expressed in all relevant cell types of the cardiovascular system, including endothelial cells. After binding of specific ligands to the ligand-binding domain, the DNA-binding site of PPAR␥ initiates the expression of its target genes. Physiological ligands include the prostaglandin D2 derivative, 15-deoxy-⌬12,14 -prostaglandin J2 (15d-PGJ2) and oxidized linoleic acid (9[S]-and 13[S]-HODE) as components of oxidized LDL

The previously mentioned TZD are one group of pharmacological PPAR␥ stimulators and have been shown to have beneficial effects on EPC and to improve endothelial function in type 2 diabetes mellitus
In this study, we investigated in vitro and in a murine in vivo model whether (i) the ARB telmisartan enhances early EPC number and function, (ii) this effect is mediated by PPAR␥, and (iii) the combination with simvastatin partly leads to an additional enhancement of EPC number and function by potentially activating alternative pathways.
Methods
Materials
Angiotensin II, simvastatin, GW9662, PD123319, TNF␣, salts and other chemicals were purchased from Sigma. Simvastatin was chemically activated by alkaline hydrolysis. Telmisartan was kindly provided by Boehringer Ingelheim.
Peripheral blood samples
Human peripheral blood samples were obtained from adult healthy volunteers by venopuncture and collected into sodium citrate containing tubes. All samples were obtained with informed consent and in accordance with the Declaration of Helsinki.
Isolation of EPC
EPC were isolated from peripheral blood or murine spleen and cultured in accordance with previously published methods [25] . Briefly 
Flow cytometry
Murine blood samples were analyzed as previously described [17] .
Following red cell lysis, the viable lymphocyte population was analyzed for sca-1-FITC (Becton Dickinson, Heidelberg, Germany) and flk-1-PE (Becton Dickinson). Isotype-identical antibodies and unstained samples served as controls in every experiment (Becton Dickinson). Cell fluorescence was measured immediately after staining using a FACSCalibur instrument (Becton Dickinson). Data were analyzed using CellQuest software (Becton Dickinson). Units of all measured components are specific events obtained after measuring 50,000 (bone marrow) or 20,000 (peripheral blood) events in a pre-specified lymphocyte gate during FACS analysis.
Carotid artery denudation
Carotid artery injury was induced as described previously [26] . Briefly (Fig. 1B) . (Fig. 2) . (Fig. 3) . (Fig. 4) . (Fig. 5) . (Fig. 6 ). (Fig. 7) . (Fig. 9) . (Fig. 10) . [27, 28] . In turn, angiotensin II blockade has been associated with improvement of EPC number and function in hypertension via antioxidant mechanisms [29] [30] [31] [18, 21, 23, 24] .
Results
EPC numbers in vitro
Endothelial cell colony forming units in vitro
Migration in vitro
Apoptosis in vitro
ROS production in vitro
DCF fluorescence was used to measure intracellular ROS production. Compared to vehicle-treated control (100%), ROS formation was significantly enhanced by angiotensin II (145 Ϯ 14% of control, P Ͻ 0.05 versus control), which was diminished by the addition of telmisartan (86 Ϯ 4% of control). Because we sought to evaluate the PPAR␥-associated telmisartan effect on oxidative
EPC counts in vivo
EPC numbers ex vivo
After cultivation of spleen-derived mononuclear cells for 7 days, the number of acLDL/lectin double-positive EPC was evaluated. Compared to the vehicle-treated control group (100%), telmisartan and simvastatin led to a significant increase of double-positive cells (138 Ϯ 6% and 163 Ϯ 27% of control, P Ͻ 0.05 versus control). The combination of telmisartan and simvastatin further enhanced EPC numbers (235 Ϯ 18% of control, P Ͻ 0.05 versus control, P Ͻ 0.05 versus telmisartan)
Endothelial cell colony forming units ex vivo
Compared to control group (100%), the number of murine EC-CFU was significantly increased in telmisartan (
Re-endothelialization in vivo
Discussion
It has been shown, that angiotensin II accelerates EPC senescence via AT1-receptor activation through induction of oxidative stress
Zhao and colleagues reported that angiotensin II induces PPAR␥ expression and ligand-mediated PPAR␥ activity via AT2-receptor activation, which is involved in neuronal cell differentiation [32] . Another study demonstrated a PPAR␥-dependent downregulation of the AT1 receptor by telmisartan independent of angiotensin II [33] [16, 17, [34] [35] [36] [37] [38] . The most important intracellular mechanism for these effects seems to be the PI3K/Akt axis. Simvastatin-induced phosphorylation and activation of Akt lead to enhanced EPC numbers, differentiation and inhibition of apoptosis, which can be effectively inhibited by PI3K blockers or over-expression of dominant-negative Akt [16, 19, 36, 38] 
